- Fusion Pharmaceuticals ( NASDAQ: FUSN ) has acquired the Investigational New Drug application for an alpha-emitting radiopharmaceutical for metastatic castrate-resistant prostate cancer asset in phase 2 from RadioMedix.
- The candidate, Ac-PSMA I&T, is a small molecule targeting prostate specific membrane antigen expressed on prostate cancers. The asset will soon be known as FPI-2265.
- Fusion ( FUSN ) also received $60M in private placement funding.
- The company plans on expanding the phase 2 program to more sites and expects to report data on 20-30 patients in Q1 2024 .
- Seeking Alpha's Quant Rating views Fusion ( FUSN ) as a hold with high marks for momentum and growth .
For further details see:
Fusion Pharmaceuticals acquiring mid-stage prostate cancer candidate from RadioMedix